SCYNEXIS to Participate in Upcoming January Investor Conferences

Rhea-AI Summary

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology firm, announced that CEO Marco Taglietti will present at two virtual investor conferences in January 2022. The events are the LifeSci Partners 11th Annual Corporate Access Event on January 7 at 10:00 a.m. ET and the H.C. Wainwright Bioconnect 2022 Virtual Healthcare Conference from January 10-13, featuring a corporate update webcast. SCYNEXIS is focused on developing innovative treatments for drug-resistant infections, including its lead asset, ibrexafungerp, approved by the FDA on June 1, 2021.

JERSEY CITY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present during two virtual investor conferences in January.

Presentation details:

• LifeSci Partners 11^th Annual Corporate Access Event
  Format: Virtual panel discussion with CEO and 1:1 meetings
  Panel Title: The Best of Both Worlds – Defining Yourself When You Fit into More Than One Basket
  Date and Time: Friday, January 7, at 10:00 a.m. ET
  Registration link: LifeSci Partners Corporate Access Event 2022

• H.C. Wainwright Bioconnect 2022 Virtual Healthcare Conference
  Format: Virtual event with webcast of corporate update presentation by Dr. Taglietti
  Date and Time: Presentation webcast will be available on-demand January 10-13 for event participants
  Registration link: H.C. Wainwright Bioconnect 2022

The latest SCYNEXIS investor presentation can be found on the corporate website here.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. We are developing our lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. The New Drug Application (NDA) for BREXAFEMME^® (ibrexafungerp tablets) was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. For more information, visit www.brexafemme.com. We are also continuing late-stage clinical development of ibrexafungerp for the prevention of recurrent VVC as well as the treatment of life-threatening invasive fungal infections in hospitalized patients. For more information, visit www.scynexis.com. 

CONTACT: 
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

Media Relations
Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
ggasaatura@lifescicomms.com

FAQ

What are the details of SCYNEXIS's upcoming investor presentations?

SCYNEXIS will present at two virtual conferences: LifeSci Partners on January 7 at 10:00 a.m. ET and H.C. Wainwright from January 10-13.

When is the LifeSci Partners Annual Corporate Access Event?

The LifeSci Partners event is scheduled for January 7, 2022, at 10:00 a.m. ET.

What is the focus of SCYNEXIS's presentations at the conferences?

The presentations will discuss SCYNEXIS's innovative medicines for drug-resistant infections, particularly ibrexafungerp.

What is ibrexafungerp and its significance?

Ibrexafungerp is SCYNEXIS's lead asset, a broad-spectrum antifungal approved by the FDA for treating difficult infections.

Where can I find more information about SCYNEXIS?

More information can be found on SCYNEXIS's official website at www.scynexis.com.